Accueil   Diary - News   All news Erytech, positive results for GRASPA®, phase III

Erytech, positive results for GRASPA®, phase III

ERYTECH PHARMA
ERYTECH,the French biopharmaceutical company that develops innovative “tumor starvation” treatments for acute leukemia and other oncology indications with unmet medical needs, reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia.

 

Read the press release